Senseonics Announces Partnership with Geo-Med to Provide Veterans Access to Eversense CGM

GERMANTOWN, Md.–(BUSINESS WIRE)–Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology
company focused on the development and commercialization of a long-term,
implantable continuous glucose monitoring (CGM) system for people with
diabetes, today has announced that it has partnered with Geo-Med, LLC, a
verified Service-Disabled Veteran-Owned Small Business (SDVOSB) to
provide access to Eversense CGM to more than 9 million covered veterans
and U.S. government personnel.

“We are pleased to partner with Geo-Med in providing veterans with
diabetes access to the latest CGM technology available. This agreement
gives veterans and Department of Defense personnel at military treatment
facilities the ability to choose our Eversense CGM System to help manage
their diabetes,” said Tim Goodnow, President and CEO of Senseonics.
“Strategic partnerships like this serve to broaden access to Eversense
for more patients. Further, consistent with our corporate values, we are
proud to partner for growth with Geo-Med, a veteran-owned business.”

The Eversense CGM System consists of a fluorescence-based sensor, a
smart transmitter worn over the sensor to facilitate data communication,
and a mobile app for displaying glucose values, trends and alerts. In
addition to featuring the first long-term and first implantable CGM
sensor, the system is also first to feature a smart transmitter that
provides wearers with discreet on-body vibratory alerts for high and low
glucose and that can be removed, recharged and re-adhered without
discarding the sensor. The sensor is inserted subcutaneously in the
upper arm by a health care provider via a brief in-office procedure.

Several recent studies, including the Veterans Administration Diabetes
Trial (VADT), show a correlation between a higher risk of death in
populations of veterans who experienced severe hypoglycemia while on an
intensive glucose lowering regiment.1 The studies also show
severe hypoglycemia appears to carry an additional risk in individuals
with higher A1c values and who may be attempting intensification of
glucose-lowering therapy, at least in older participants with more
advanced diabetes.1

In the PRECISE2, PRECISE II3 and PRECISION4
studies, Eversense CGM has consistently demonstrated a reduction in A1c
while demonstrating detection of hypoglycemia up to 95%. Predictive
alerts and accuracy during the hypoglycemic ranges have been shown to
help people with diabetes reduce the incidence of hypoglycemic events,
which could be very beneficial to this veteran population.

“We are proud to partner with companies like Senseonics to offer the
latest CGM technology to our veterans,” said Geo-Med CEO Mike Locke.
“Being a Veteran myself, our mission is to deliver superior customer
service, uncompromised product quality and business integrity for our
nation’s finest at VA Medical Centers and Military Treatment Facilities
all over the country. We are determined to provide the highest level of
service to all those who SERVED—past and present. This partnership is
another example of us fulfilling our mission.”

Patients who are interested in getting started on Eversense can sign up
at www.eversensediabetes.com/get-started-today.
Physicians, nurse practitioners or physician assistants interested in
offering the Eversense CGM System for their patients can contact
844-SENSE4U (844-736-7348).

 
1 Stephen N. Davis, William Duckworth, Nicholas Emanuele, et al.;
Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death
in the Veterans Affairs Diabetes Trial. Diabetes Care Jan 2019, 42
(1) 157-163; DOI: 10.2337/dc18-114
2 Kropff, J. PRECISE. Diabetes Care, 40(1), 63-68.
3 Christiansen MP, PRECISE II. Diabetes Technology & Therapeutics.
2018;20(3):197-206.
4 PRECISION Trial. Data on file. Senseonics 2018.
 

About Eversense

The Eversense® Continuous Glucose Monitoring (CGM) System is
indicated for continually measuring glucose levels in persons age 18 and
older with diabetes for up to 90 days. It is intended to complement, not
replace, fingerstick blood glucose monitoring. The sensor insertion and
removal is performed by a health care provider. The Eversense CGM System
is a prescription device; patients should talk to their health care
provider to learn more. For important safety information, see https://eversensediabetes.com/safety-info/.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of transformational glucose
monitoring products designed to help people with diabetes confidently
live their lives with ease. Senseonics’ CGM systems, Eversense®
and Eversense® XL, include a small sensor inserted completely
under the skin that communicates with a smart transmitter worn over the
sensor. The glucose data is automatically sent every 5 minutes to a
mobile app on the user’s smartphone.

About Geo-Med, LLC

Geo-Med, LLC is a verified Service-Disabled Veteran-Owned Small Business
(SDVOSB) medical and surgical supplier, founded in 2004 by a veteran of
the United States Marine Corps. We have partnered with leading
manufacturers that share our commitment to client satisfaction to
provide a broad range of medical and surgical products to our Veteran
Administration Medical Center and Department of Defense Military
Treatment Facility customers. We take great pride in knowing our
products and the service we provide affect the care of our veterans,
active duty military personnel and their families. Geo-Med serves
federal customers nationally and abroad.

Contacts

Senseonics Investor Relations Contact:
Lynn Lewis or Philip
Taylor
Investor Relations
415-937-5406
[email protected]

Media Contact:
SignalWest Public Relations
Jeff
Christensen, 831-566-0275
[email protected]

error: Content is protected !!